AZD 6088Alternative Names: AZD6088
Latest Information Update: 15 Feb 2010
At a glance
- Originator AstraZeneca
- Mechanism of Action Muscarinic M1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 28 Jan 2010 Discontinued - Phase-I for Neuropathic pain in United Kingdom (PO)
- 30 Jun 2009 Phase-I clinical trials in Neuropathic pain in United Kingdom (PO)